Storr 1986.

Methods	Design: single‐centre, randomised, double‐blind, parallel‐group, placebo‐controlled trial Sponsor: SETRHA and The Royal Alexandra Hospital Centenary Fund
Participants	Setting: Royal Alexandra Hospital for Sick Children, Brighton, UK Eligible: 29 Randomly assigned: 15 (beclomethasone); 14 (placebo) Analysed: 15 (beclomethasone); 13 (placebo) Gender (male): 62.1% Age, years, mean (range): 3.6 (1.6‐5.6) Inclusion criteria: During the 6 months before the study, all had had severe recurrent wheezing episodes and had responded well to treatment with nebulised bronchodilator agents. The number of previous hospital admissions for asthma ranged from 4 to 14, with at least 2 in the previous 6 months. None of the participants were satisfactorily controlled before the study began Exclusion criteria: not reported Previous regular use of ICS: none of the participants
Interventions	Test group: Beclomethasone, 300 μg/d Control group: matching placebo Treatment was given 3 times daily via jet nebuliser for 6 months
Outcomes	Mean daily symptom scores Symptom‐free days Change in height over time (cm)
Notes	Treatment compliance was not measured
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details provided
Allocation concealment (selection bias)	Low risk	Allocation code was kept by the hospital pharmacist and by Allen and Hanburys Ltd
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Use of matching placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Use of matching placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only 1 participant did not complete the study
Selective reporting (reporting bias)	Low risk	Study protocol is not available, but published reports include all expected outcomes, including those that were prespecified
Other bias	Unclear risk	Method of height measure not reported